CYP21A2 and congenital adrenal hyperplasia: Among the typical clinical symptoms and findings in CAH, neither the subject with a detected CYP21A2 variation nor the other seven subjects with serum 17OHP levels ≥30 nmol/L presented hyperandrogenic signs or symptoms as expected, since none of them were classified as CAH after CYP21A2-gene analysis.